
Protagonist Therapeutics (PTGX) Stock Forecast & Price Target
Protagonist Therapeutics (PTGX) Analyst Ratings
Bulls say
Protagonist Therapeutics is seeing strong financial performance and many upcoming milestone payments, with a forecasted runway through at least 2028. The recent approval and launch of Icotyde for psoriasis, as well as potential future approvals for other indications, could drive significant revenue and support the company's peptide platform and other pipeline programs. With multiple shots on goal and a strong cash balance, our outlook remains positive and our price target has increased from $112 to $118.
Bears say
Protagonist Therapeutics is facing a difficult road ahead with its Ico drug, as patient adoption rates and market expansion projections are heavily dependent on patient preference for biologics. Additionally, while their wholly owned programs are on track, their estimated timelines for completion and initiation of studies are pushed back, which could hinder potential revenue growth. Finally, their partnership with Takeda for Rusfertide provides a potential positive revenue stream in the future, but may not be enough to offset the challenges facing the company.
This aggregate rating is based on analysts' research of Protagonist Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Protagonist Therapeutics (PTGX) Analyst Forecast & Price Prediction
Start investing in Protagonist Therapeutics (PTGX)
Order type
Buy in
Order amount
Est. shares
0 shares